Treatment
HRS-4642 clinical trials
We’re tracking 12 recruiting studies that include HRS-4642, each written for real people, not researchers, below.
Recruiting studies
- NCT06547736RecruitingPhase 2
Precision treatment for advanced pancreatic cancer
This trial tests personalized therapies for people with advanced pancreatic cancer that has spread or cannot be removed. It aims to find the best treatment based on your tumor's unique features.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06620848RecruitingPhase 2
A trial of HRS-4642 alone or with adebrelimab for advanced bile duct cancer
This trial tests a new drug, HRS-4642, either by itself or combined with another drug called adebrelimab, for people whose advanced bile duct cancer has come back or gotten worse after standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07232875RecruitingPhase 3
New drug combo for first-line advanced pancreatic cancer
This trial tests a new drug (HRS-4642) combined with standard chemotherapy as a first treatment for advanced pancreatic cancer that has spread. It may help shrink tumors and extend life.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07296341RecruitingPhase 1/Phase 2
HRS-4642 plus other therapies for pancreatic cancer
This study tests an experimental drug (HRS-4642) combined with other cancer treatments for people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to see if the combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT06938282RecruitingPhase 2
Study of HRS-4642 with immunotherapy and chemo for pancreatic cancer
This trial tests a new drug combination for pancreatic cancer that has not been treated before. It may help shrink tumors or make surgery possible for people with advanced or borderline resectable disease.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06520488RecruitingPhase 1/Phase 2
HRS-4642 combined with other cancer drugs for advanced tumors
This trial tests a new drug, HRS-4642, combined with other cancer treatments for people with advanced solid tumors. It looks at how well the combination works and if it is safe for you.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06427239RecruitingPhase 1/Phase 2
HRS-4642 and adebrelimab for advanced pancreatic cancer
This trial tests a combination of two drugs (HRS-4642 and adebrelimab) for people with advanced pancreatic cancer that has not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06587061RecruitingPhase 2
HRS-4642 plus AG before and after surgery for pancreatic cancer
This trial tests a combination of two medications (HRS-4642 and AG) given before and after surgery for pancreatic cancer that can be removed. The goal is to see if this treatment helps prevent the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07240766RecruitingPhase 2
New drug combo for KRAS G12D pancreatic cancer
This trial tests a new targeted drug (HRS-4642) combined with another drug (Nimotuzumab) and two chemotherapy drugs for people with a specific type of pancreatic cancer that has a KRAS G12D mutation. The goal is to see if this combination can help make the tumor smaller and possibly removable by surgery.
Hangzhou, ZhejiangAges 18–75 - NCT06770452RecruitingPhase 2
HRS-4642 combo for first-line advanced pancreatic cancer
This trial tests a new targeted drug (HRS-4642) combined with nimotuzumab and chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. It's for those who haven't had treatment for advanced disease yet.
Hangzhou, ZhejiangAges 18–75 - NCT07131514RecruitingPhase 2
Combination therapy for pancreatic cancer before and after surgery
This trial tests if giving a combination of four drugs before and after surgery can help treat pancreatic cancer. The drugs include HRS-4642, gemcitabine, nab-paclitaxel, and adebrelimab. It may help shrink the tumor before surgery and lower the chance of cancer coming back afterward.
ShanghaiAges 18–80 - NCT07438106RecruitingPhase 2
HRS-4642 with chemo to shrink pancreatic cancer before surgery
This trial tests a new drug, HRS-4642, combined with a two-drug chemotherapy (nab-paclitaxel and gemcitabine) for people with locally advanced pancreatic cancer that has not spread. The goal is to shrink the tumor enough so it can be surgically removed.
NanjingAges 18–75
What HRS-4642 is being studied for
Conditions with recruiting HRS-4642 studies.
Common questions
- Are there clinical trials studying HRS-4642?
- Yes. Clin2 currently lists 12 recruiting studies that include HRS-4642, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a HRS-4642 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is HRS-4642 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether HRS-4642 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.